These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20171588)

  • 1. The unusual presentation of gastric adenocarcinoma as a testicular mass: a favorable response to docetaxel and Cisplatin plus oral tegafur/uracil and leucovorin.
    Yang KC; Chao Y; Luo JC; Kuo JY; Lee RC; Li AF; Li CP
    J Chin Med Assoc; 2010 Feb; 73(2):88-92. PubMed ID: 20171588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
    Li CP; Chen JS; Chen LT; Yen CJ; Lee KD; Su WP; Lin PC; Lu CH; Tsai HJ; Chao Y
    Br J Cancer; 2010 Oct; 103(9):1343-8. PubMed ID: 20924378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer.
    Oh SC; Park KH; Choi IK; Yoon SY; Kim SJ; Seo JH; Choi CW; Kim BS; Shin SW; Kim JS; Kim YH
    Br J Cancer; 2005 Mar; 92(5):827-31. PubMed ID: 15726097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
    Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
    Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma.
    Kim YH; Kim BS; Seo JH; Choi CW; Kim JS; Chun HJ; Hyun JH; Kim JS
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):64-8. PubMed ID: 10442365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
    Chen JS; Rau KM; Chen YY; Huang JS; Yang TS; Lin YC; Liau CT; Lee KD; Su YC; Kao RH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):819-25. PubMed ID: 18663448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication.
    Ma Y; Qin H; Zheng Q; Wang Y; Wang Z; Yang Z
    Med Oncol; 2010 Dec; 27(4):1089-95. PubMed ID: 19885749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy].
    Shibata N; Tamai M; Ikeda K
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):119-22. PubMed ID: 7826066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
    Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
    Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma.
    Guo Mg; Zheng Q; zhong Di J; Yang Z
    World J Surg Oncol; 2014 May; 12():150. PubMed ID: 24885421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
    Woo IS; Moon DH; Shim BY; Lee MA; Byun JH; Kim KW; Kang JH; Choi MG; Chung IS; Hong YS; Park SY; Lee KS
    Jpn J Clin Oncol; 2005 Jan; 35(1):13-7. PubMed ID: 15681598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
    Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of lower dose UFT without leucovorin in metastatic gastric cancer patients.
    Somali I; Meydan N; Tarhan MO; Oztop I; Alacacioglu A; Yilmaz U
    J BUON; 2009; 14(3):429-33. PubMed ID: 19810134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Three patients with advanced nonresectable and recurrent gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by CPT-11 administration].
    Kobayashi A; Hirose T; Yamada T
    Gan To Kagaku Ryoho; 2002 Aug; 29(8):1439-45. PubMed ID: 12214474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
    Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
    Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer.
    Ichikura T; Tomimatsu S; Okusa Y; Yahara T; Uefuji K; Tamakuma S
    Cancer Chemother Pharmacol; 1996; 38(5):401-5. PubMed ID: 8765432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
    Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
    Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.